719 Phase 1 study of the porcupine (PORCN) inhibitor RXC004 in combination with the PD-1 inhibitor nivolumab in patients with advanced solid tumors
Natalie Cook(Manchester Academic Health Science Centre), Ruth Plummer(National Health Service), Aglaia Skolariki(MRC Clinical Trials Unit at UCL), Alastair Greystoke(Newcastle University), Ana OrtegoFranco(University of Manchester), Salma ElBadri(Oxford University Hospitals NHS Trust), Cienne Morton(Guy's and St Thomas' NHS Foundation Trust), Jane Robertson, Shybi Mohamedkhan(Royal Marsden Hospital), Eimear Flanagan, Catherine Eagle, Juanita Lopez(Institute of Cancer Research), Sarah P. Blagden(Churchill Hospital), Simon D. Woodcock, Craig Tilston(Redx Pharma (United Kingdom)), Debashis Sarker(King's College - North Carolina), Saira Bashir(Newcastle University), Helen Timmis(4D Pharma (United Kingdom)), C. W. Phillips, Louise Goodwin(Redx Pharma (United Kingdom))
Cited by 2
Related Papers
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|604
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
|New England Journal of Medicine|2020|406